The genesis of new blood vessels is the culmination of angiogenic activity
which is responsible for the spreading of the tumors and other malignant masses. The
blood supply also provides nourishment to non-malignant tissues and helps in their
maintenance, growth, and proliferation. The major biological factors that significantly
favor the angiogenic processes includes vascular endothelial growth factors (VEGFs),
tumor necrosis factors (TNFs), and fibroblast growth factors (FGFs). The disruption
and inhibition of angiogenic growth factors and their biochemical pathways during the
cancer cycle are among the obvious choices to control the growth and proliferation of
cancers. The current work deals in details about the growth factors, their roles,
contextual biomechanics, and approaches to control angiogenesis through different
inhibitory mechanisms involving biochemical pathways, growth factors, and structural
motifs, playing part in the angiogenesis. The approaches to find novel molecular
templates, new chemical entities, bio-macromolecular substrates, and probable drug
leads for anti-angiogenic pharmacology are discussed. The chapter enlists various antiangiogenesis
drugs, under clinical trials, new chemical entities, and other biochemical
and recombinant therapeutic agents, used either as mono or as combination therapy in
treatment of various forms of cancers, especially breast and prostate cancers.
Keywords: Angiogenesis, Angiogenin, Angiostatin, Antiangiogensis, Bevacizumab,
Decorin, FGF, Ephrin, Endostatin, Interferon, Interleukin, Integrin, Matrix Metallo-
Proteinases (MMP), TNFα, Thrombospondin, US-FDA Approved Anti-Cancer Drugs,
Vitaxin.
